<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02939937</url>
  </required_header>
  <id_info>
    <org_study_id>9411257013</org_study_id>
    <nct_id>NCT02939937</nct_id>
  </id_info>
  <brief_title>Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis</brief_title>
  <official_title>a Phase II Double Blind, Randomized, Placebo Controlled Trial of Effect of Phenytoin on the Ganglion Cell Inner Plexiform Layer (GCIPL) Thickness and Visual Field in Patients With a First Episode of Acute Optic Neuritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Optic neuritis typically occurs in young (mean age, 32 years), female (77%) patients, and it
      presents as subacute monocular visual loss that develops over several days.

      As yet, treatment with intravenous corticosteroid for optic neuritis had no long-term
      beneficial effect on vision.

      There are a number of factors that contribute to nerve fibre damage including increased level
      of sodium, so blocking sodium entry could help to protect them against damage.

      The main objective of the study is determine whether phenytoin (which blocks sodium entry)
      can protect nerve fibre and improve final visual function after optic neuritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 9, 2017</start_date>
  <completion_date type="Actual">January 2, 2019</completion_date>
  <primary_completion_date type="Actual">November 11, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>participant , investigator</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal Ganglion Cell Inner Plexiform Layer Thickness</measure>
    <time_frame>Measured at baseline and month 1, 6</time_frame>
    <description>ganglion cell inner plexiform layer thickness measure in 8 sectors by Heidelberg spectral-domain Optical Coherence Tomography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Macular Layer Thickness</measure>
    <time_frame>Measured at baseline and month 1, 6</time_frame>
    <description>macular layer thickness measure in 8 sectors by Heidelberg spectral domain Optical Coherence Tomography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>at baseline and month 6</time_frame>
    <description>Best corrected visual acuity is converted to logMAR (logarithms of minimum angle of resolution) by statistical calculation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Field Mean Deviation in Decibel</measure>
    <time_frame>Measured at baseline and month 6</time_frame>
    <description>The visual field is performed by the Swedish interactive thresholding algorithm standard 24-2 perimeter (Carl Zeiss mediated, Dublin, California).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal Nerve Fibre Layer Thickness in Micrometer</measure>
    <time_frame>Measured at baseline and month1 ,6</time_frame>
    <description>Retinal nerve fibre layer thickness measure in 8 sectors by Heidelberg spectral-domain Optical Coherence Tomography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Optic Neuritis</condition>
  <arm_group>
    <arm_group_label>phenytoin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients received phenytoin 100mg three time daily up to 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients received placebo 100 mg three time daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenytoin</intervention_name>
    <description>100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.</description>
    <arm_group_label>phenytoin</arm_group_label>
    <other_name>epanutin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>100 mg placebo three time daily for three months, and phenytoin levels will be taken at one and three months later.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  isolated, unilateral, first acute optic neuritis (confirmed by neuroophthalmologist)

          -  willing to receive a steroidal regimen

          -  no pathologic finding in first oct

          -  no pathology and history of optic neuritis in contralateral eye

          -  &lt;14 days since onset visual loss

        Exclusion Criteria:

          -  Contraindication or known allergy to Phenytoin

          -  Use of a calcium channel or sodium channel blocker in the past 2 months

          -  Corticosteroid use in the past 2 months

          -  Pregnancy

          -  Significant cardiac, renal or liver abnormalities

          -  Prior clinical episode of optic neuritis in either eye

          -  Bilateral acute optic neuritis

          -  Known ocular or neurological conditions or abnormalities other than refractive error
             that impair visual function

          -  Refractive error of greater than +5 or -5 diopters

          -  Any condition that may interfere with performance of Optical Coherence Tomography
             (OCT): corneal, lens or fundoscopic abnormality, a co-morbid ocular condition not
             related to optic neuritis as detected on the OCT reading
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eye Research Center Farabi Hosoital</name>
      <address>
        <city>Tehran</city>
        <zip>3542168325</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>August 8, 2016</study_first_submitted>
  <study_first_submitted_qc>October 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2016</study_first_posted>
  <results_first_submitted>January 5, 2019</results_first_submitted>
  <results_first_submitted_qc>July 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 12, 2019</results_first_posted>
  <last_update_submitted>July 5, 2019</last_update_submitted>
  <last_update_submitted_qc>July 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Optic Neuritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenytoin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT02939937/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT02939937/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT02939937/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phenytoin</title>
          <description>patients received phenytoin 100mg three time daily up to 3 months
Phenytoin: 100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>patients received placebo 100 mg three time daily for 3 months
placebo: 100 mg placebo three time daily for three months, and phenytoin levels will be taken at one and three months later.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21">5 patients had drug reaction and 1 patient excluded from study,</participants>
                <participants group_id="P2" count="50">3 patients excluded from study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phenytoin</title>
          <description>patients received phenytoin 100mg three time daily up to 3 months
Phenytoin: 100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>patients received placebo 100 mg three time daily for 3 months
placebo: 100 mg placebo three time daily for three months, and phenytoin levels will be taken at one and three months later.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="71"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>6 subjects in phenytoin group and 3 subjects in placebo group were excluded from our study and this left 15 patients in phenytoin and 47 subjects in placebo group to be analysed.</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Iran</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="47"/>
                    <count group_id="B3" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Retinal Ganglion Cell Inner Plexiform Layer Thickness</title>
        <description>ganglion cell inner plexiform layer thickness measure in 8 sectors by Heidelberg spectral-domain Optical Coherence Tomography</description>
        <time_frame>Measured at baseline and month 1, 6</time_frame>
        <population>incomplete follow up from baseline to 6 month</population>
        <group_list>
          <group group_id="O1">
            <title>Phenytoin</title>
            <description>patients received phenytoin 100mg three time daily up to 3 months
Phenytoin: 100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients received placebo 100 mg three time daily for 3 months
placebo: 100 mg placebo three time daily for three months, and phenytoin levels will be taken at one and three months later.</description>
          </group>
        </group_list>
        <measure>
          <title>Retinal Ganglion Cell Inner Plexiform Layer Thickness</title>
          <description>ganglion cell inner plexiform layer thickness measure in 8 sectors by Heidelberg spectral-domain Optical Coherence Tomography</description>
          <population>incomplete follow up from baseline to 6 month</population>
          <units>micron</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.56" spread="6.61"/>
                    <measurement group_id="O2" value="34.65" spread="8.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" spread="6.61"/>
                    <measurement group_id="O2" value="29.42" spread="5.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.70" spread="5.56"/>
                    <measurement group_id="O2" value="32.12" spread="9.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Macular Layer Thickness</title>
        <description>macular layer thickness measure in 8 sectors by Heidelberg spectral domain Optical Coherence Tomography</description>
        <time_frame>Measured at baseline and month 1, 6</time_frame>
        <population>incomplete follow up</population>
        <group_list>
          <group group_id="O1">
            <title>Phenytoin</title>
            <description>patients received phenytoin 100mg three time daily up to 3 months
Phenytoin: 100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients received placebo 100 mg three time daily for 3 months
placebo: 100 mg placebo three time daily for three months, and phenytoin levels will be taken at one and three months later.</description>
          </group>
        </group_list>
        <measure>
          <title>Macular Layer Thickness</title>
          <description>macular layer thickness measure in 8 sectors by Heidelberg spectral domain Optical Coherence Tomography</description>
          <population>incomplete follow up</population>
          <units>micron</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262.73" spread="22.02"/>
                    <measurement group_id="O2" value="265.98" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255" spread="19.72"/>
                    <measurement group_id="O2" value="264.39" spread="22.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269" spread="28.29"/>
                    <measurement group_id="O2" value="268.37" spread="22.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Best Corrected Visual Acuity</title>
        <description>Best corrected visual acuity is converted to logMAR (logarithms of minimum angle of resolution) by statistical calculation.</description>
        <time_frame>at baseline and month 6</time_frame>
        <population>incomplete follow up</population>
        <group_list>
          <group group_id="O1">
            <title>Phenytoin</title>
            <description>patients received phenytoin 100mg three time daily up to 3 months
Phenytoin: 100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients received placebo 100 mg three time daily for 3 months
placebo: 100 mg placebo three time daily for three months, and phenytoin levels will be taken at one and three months later.</description>
          </group>
        </group_list>
        <measure>
          <title>Best Corrected Visual Acuity</title>
          <description>Best corrected visual acuity is converted to logMAR (logarithms of minimum angle of resolution) by statistical calculation.</description>
          <population>incomplete follow up</population>
          <units>log mar</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="0.98"/>
                    <measurement group_id="O2" value="1" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.067"/>
                    <measurement group_id="O2" value="0.13" spread="0.448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Field Mean Deviation in Decibel</title>
        <description>The visual field is performed by the Swedish interactive thresholding algorithm standard 24-2 perimeter (Carl Zeiss mediated, Dublin, California).</description>
        <time_frame>Measured at baseline and month 6</time_frame>
        <population>incomplete follow up</population>
        <group_list>
          <group group_id="O1">
            <title>Phenytoin</title>
            <description>patients received phenytoin 100mg three time daily up to 3 months
Phenytoin: 100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients received placebo 100 mg three time daily for 3 months
placebo: 100 mg placebo three time daily for three months, and phenytoin levels will be taken at one and three months later.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Field Mean Deviation in Decibel</title>
          <description>The visual field is performed by the Swedish interactive thresholding algorithm standard 24-2 perimeter (Carl Zeiss mediated, Dublin, California).</description>
          <population>incomplete follow up</population>
          <units>db</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline visual field mean deviation (MD)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.07" spread="11.41"/>
                    <measurement group_id="O2" value="-17.76" spread="11.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months MD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.89" spread="4.46"/>
                    <measurement group_id="O2" value="-5.16" spread="7.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retinal Nerve Fibre Layer Thickness in Micrometer</title>
        <description>Retinal nerve fibre layer thickness measure in 8 sectors by Heidelberg spectral-domain Optical Coherence Tomography</description>
        <time_frame>Measured at baseline and month1 ,6</time_frame>
        <population>incomplete follow up</population>
        <group_list>
          <group group_id="O1">
            <title>Phenytoin</title>
            <description>patients received phenytoin 100mg three time daily up to 3 months
Phenytoin: 100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>patients received placebo 100 mg three time daily for 3 months
placebo: 100 mg placebo three time daily for three months, and phenytoin levels will be taken at one and three months later.</description>
          </group>
        </group_list>
        <measure>
          <title>Retinal Nerve Fibre Layer Thickness in Micrometer</title>
          <description>Retinal nerve fibre layer thickness measure in 8 sectors by Heidelberg spectral-domain Optical Coherence Tomography</description>
          <population>incomplete follow up</population>
          <units>micron</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.8" spread="36.56"/>
                    <measurement group_id="O2" value="124.87" spread="47.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.85" spread="8.64"/>
                    <measurement group_id="O2" value="97.41" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.7" spread="20.03"/>
                    <measurement group_id="O2" value="78.61" spread="18.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phenytoin</title>
          <description>patients received phenytoin 100mg three time daily up to 3 months
Phenytoin: 100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>patients received placebo 100 mg three time daily for 3 months
placebo: 100 mg placebo three time daily for three months, and phenytoin levels will be taken at one and three months later.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>steven johnson</sub_title>
                <description>steven johnson syn,Stevens–Johnson syndrome (SJS) is a type of severe skin reaction</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin reaction</sub_title>
                <description>sever skin reaction to drug except sjs</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Shorter follow up
Poor compliance for oral drug intake</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>dr.alireza gholizade</name_or_title>
      <organization>assistant</organization>
      <phone>989112550646</phone>
      <email>a.gholizade13@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

